FDA Guidance for Inflammatory Bowel Disease Drug Development: Endpoints, Trial Design, and Efficacy Expectations

For teams building IBD programs, the FDA's disease-specific guidances are the reference point that shapes protocol design, endpoint selection, and the evidentiary bar a submission must clear. Because ulcerative colitis and Crohn's disease are governed by separate documents—now joined by a dedicated pediatric guidance—regulatory and clinical strategists need a clear read of what each requires and where their expectations diverge before committing to a trial design.

This analysis maps the current FDA guidance landscape for IBD drug development. It identifies the governing documents, their status, and the cross-cutting guidances that bear on these programs, then walks through the coprimary endpoint structure, the induction-and-maintenance trial architecture, and the corticosteroid-free remission standard the agency sets for demonstrating efficacy.

Want to ask Rhizome your own regulatory questions? Try it for free.

FDA guidance for inflammatory bowel disease drug development: endpoints, trial design, and efficacy expectations

Drug development for inflammatory bowel disease (IBD) in the United States is now governed by a set of disease-specific FDA guidances that separate ulcerative colitis (UC) from Crohn's disease (CD) and add a dedicated pediatric document. The two adult guidances share a common architecture built around coprimary endpoints that pair a symptom measure with a centrally read endoscopic measure, randomized placebo-controlled induction and maintenance, and durable, corticosteroid-free remission as the efficacy bar. This overview summarizes what each document sets out and where the two indications diverge.

The current guidance set

Three documents define the disease-specific landscape, and all three are currently in draft form:

  • Ulcerative Colitis: Developing Drugs for Treatment, draft guidance issued April 28, 2022 3.
  • Crohn's Disease: Developing Drugs for Treatment, draft guidance issued April 28, 2022 2.
  • Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment, draft guidance issued July 19, 2024 1.

The UC and CD drafts were released as companion documents on the same day and use parallel structures, which makes cross-reading them straightforward. Sponsors also draw on cross-cutting FDA guidances that are not IBD-specific but bear directly on these programs, including Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (final, March 2019) 12 and Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (draft, February 2023) 14. A separate final guidance covers irritable bowel syndrome (2012) 17, a distinct indication that should not be conflated with IBD.

Ulcerative colitis

Endpoints

The UC guidance is built on the modified Mayo score (mMS). FDA defines clinical remission as an mMS of 0 to 2 with each of three components satisfied: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and a centrally read endoscopy subscore of 0 or 1, where the score of 1 is modified to exclude friability 60. The proportion of subjects achieving clinical remission is the recommended primary endpoint for the induction trial 60.

For the endoscopic component, FDA defines endoscopic improvement as a centrally read endoscopy subscore of 0 or 1 (with 1 modified to exclude friability) and endoscopic remission as a subscore of 0 19. The recommended clinical response secondary endpoint is a decrease from baseline in mMS of at least 2 points and at least 30 percent, together with a decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 55.

Corticosteroid-free remission is defined as being in clinical remission at the end of the controlled trial (for example, 52 weeks) with no corticosteroid exposure during a prespecified period, such as at least 8 to 12 weeks, before that assessment; FDA also wants the proportion achieving corticosteroid-free remission reported among subjects using corticosteroids at enrollment 19. Histologic response/remission remains exploratory: FDA states there is no scientific consensus on a definition or scoring system for histologic resolution of mucosal inflammation in UC, so sponsors must justify any proposed endpoint definition, grading scale, and scoring technique 19. To support maintenance without repeated endoscopy, FDA recommends interim clinical assessments based on the noninvasive mMS components (stool frequency and rectal bleeding subscores) at prespecified time points through the last visit 19.

Trial design

FDA recommends a randomized, double-blind, placebo-controlled program capable of showing both short-term benefit and durable long-term benefit 20. Two designs are acceptable 20:

  • Induction followed by randomized-withdrawal maintenance: a randomized, placebo-controlled induction trial assesses short-term benefit, after which only induction responders are re-randomized to active drug or placebo, with efficacy reassessed at the end of maintenance (for example, 52 weeks).
  • Treat-through: subjects are randomized once at baseline to active drug or placebo and treated continuously through 52 weeks, with the primary endpoint assessed at the end of treatment, periodic earlier assessments to characterize onset, and early-escape criteria for subjects who worsen or fail to improve.

Placebo responders at the end of induction should continue to receive blinded placebo in maintenance 20. The trial population should reflect the clinically relevant population, with balanced representation of biologic-naive subjects and those who have failed prior biologics or other advanced therapies 20. For drugs aimed at mildly to moderately active UC, FDA specifies entry criteria of an mMS of at least 4, an endoscopy subscore of at least 2, and a rectal bleeding subscore of at least 1 20.

FDA emphasizes endoscopic rigor: colonoscopy (rather than sigmoidoscopy) to document disease activity across all involved colonic segments, central reading as the primary scoring approach for the endoscopic component of primary and secondary endpoints, blinding of both the endoscopist and the central readers to treatment assignment, and a prespecified process for handling reader discrepancies such as third-reader adjudication 55.

Efficacy expectations

A UC program must demonstrate efficacy in both phases: clinical response at the end of induction and maintenance of clinical remission in the maintenance phase, with induction clinical response used to re-randomize subjects into maintenance in the induction/maintenance design 55. Durability is central. In randomized-withdrawal designs FDA assesses remission in the subset entering maintenance in remission, while in treat-through designs it looks at the proportion achieving clinical remission at both an early time point (for example, 8 weeks) and a late time point (for example, 52 weeks) 19. Sponsors developing novel patient-reported outcome (PRO) instruments may submit a PRO development proposal, and to support labeling claims should show an adequate number of patients have the symptom at baseline with sufficient severity to measure clinically meaningful improvement, preferably supported by anchor-based analyses 21.

Safety

FDA notes the minimum acceptable safety database is drug-specific, varying with new-molecular-entity status, supportive data from other populations, class-related and anticipated adverse events, and nonclinical findings 132. For chronic therapy, a sufficient number of subjects should be exposed to the to-be-marketed regimen for at least 52 weeks 132. Sponsors proposing shorter washout periods should acknowledge the increased early risk of serious infections and build in monitoring and mitigation, evaluate neutralizing antidrug antibodies and their impact on efficacy and safety for therapeutic proteins, and prospectively plan formal safety comparisons using risk differences, relative risks, or hazard ratios with confidence intervals 132.

Crohn's disease

Endpoints

The CD guidance also uses coprimary endpoints that capture both signs and symptoms and underlying mucosal inflammation 59. FDA recommends clinical remission defined as a CDAI score below 150 59, paired with an endoscopic endpoint scored on the SES-CD via ileocolonoscopy 495459. Endoscopic remission is defined as SES-CD of 0 to 2, with an alternative acceptable definition of SES-CD of 0 to 4 provided no individual subscore exceeds 1 52. Endoscopic response is a 50 percent reduction from baseline in the SES-CD 52. If endoscopic remission cannot realistically be achieved within the study duration, endoscopic response may serve as the endoscopic coprimary endpoint, with endoscopic remission moved to a secondary endpoint 5272.

FDA is candid that its thinking has evolved because the CDAI is poorly associated with intestinal inflammation, and it encourages sponsors to explore additional symptoms not captured by the CDAI using fit-for-purpose PRO instruments 5450. In practice, the draft still anchors clinical remission on CDAI below 150 while pushing sponsors toward better symptom measures and mandatory endoscopic pairing 54505259. A composite endpoint, the proportion of subjects achieving both clinical remission and endoscopic remission, is recommended 5052, along with assessment of the absolute change in SES-CD from baseline 50. Corticosteroid-free remission mirrors the UC definition: clinical remission at trial end with no corticosteroid exposure during a prespecified window such as 8 to 12 weeks, reported among subjects using corticosteroids at enrollment 52.

Trial design

As in UC, FDA recommends a randomized, double-blind, placebo-controlled program able to show that early benefit is maintained long term 64. The primary approach is a randomized, placebo-controlled induction trial followed by randomized-withdrawal maintenance, in which subjects achieving initial clinical or endoscopic response are re-randomized to active drug or placebo and reassessed at the end of maintenance (for example, 52 weeks) 64. A treat-through strategy is also recognized for assessing durability, with clinical remission and SES-CD assessed at early and late time points such as 8 and 52 weeks 50. Placebo responders at the end of induction should continue on blinded placebo in maintenance 64.

For moderately to severely active Crohn's disease, FDA specifies baseline entry criteria of a CDAI of at least 220 and an SES-CD of at least 6 (or at least 4 for isolated ileal disease), which functions as the endoscopic eligibility threshold 64. Enrollment should span the full range of moderate-to-severe activity with a balanced mix of biologic-naive subjects and biologic or advanced-therapy failures 64.

Efficacy expectations

FDA states that demonstrating treatment effects on both distinct endpoints, the clinical endpoint and the endoscopic endpoint, is necessary to establish clinical benefit in Crohn's disease, and that sponsors should show statistical significance on both coprimary analyses 5972. Durability is assessed through the maintenance analyses described above, and a secondary endpoint should capture the proportion achieving both clinical and endoscopic remission at the end of the study 50. Where adequate PRO instruments are not yet available, FDA expects sponsors to develop or modify instruments based on patient input and validate them before phase 3 use, and to ensure any PRO is well-defined and reliable so it can contribute meaningfully to benefit-risk assessment 8583.

Scope limitations

The adult Crohn's guidance explicitly excludes stricturing and fistulizing disease, which encompasses fistulizing and perianal Crohn's disease, and it does not address pediatric drug development 117. Sponsors pursuing those populations therefore cannot rely on this document for endpoint or design recommendations and should engage FDA directly.

Pediatric IBD

The 2024 pediatric IBD draft is designed around extrapolation of efficacy from adults. FDA recommends using the same primary and secondary endpoints and the same timing of assessment in pediatric subjects as in adults to facilitate that extrapolation 4037. Sponsors should specify enrollment targets for each age cohort to ensure adequate representation across the age range and body weights, with example cohorts of 2 to 5 years, 6 to 11 years, and 12 to 17 years 40, and should use PK-based dose selection, including PK or PK/PD studies to determine an appropriate dose 44.

Endpoints track the adult framework with pediatric instruments. For pediatric UC, the primary endpoint is clinical remission defined by an mMS of 0 to 2 built from stool frequency, rectal bleeding, and centrally read endoscopy components 40. For pediatric CD, FDA recommends coprimary endpoints of clinical remission (PCDAI of 10 or below) and endoscopic remission (SES-CD 0 to 2, or alternatively 0 to 4 with no individual subscore above 1), with clinical response, endoscopic response, and corticosteroid-free remission as secondary endpoints 37. The guidance carries over centralized endoscopy reading, blinding of endoscopists and central readers, and discrepancy adjudication, and it distinguishes rerandomized maintenance from treat-through designs for durable-remission assessment 4029. Like the adult CD document, the pediatric guidance does not address stricturing or fistulizing disease, although its PCDAI does include perirectal disease features such as indolent or active fistula, drainage, and abscess 12411069.

Cross-indication themes for reviewers

Across the adult UC and CD guidances, four expectations are consistent and worth internalizing early in program design. First, efficacy rests on coprimary endpoints that combine a symptom or clinical-activity measure with a centrally read endoscopic measure, so no program should plan on a symptom-only endpoint 596052. Second, the program must demonstrate both induction and durable maintenance of remission, with 52-week maintenance data and corticosteroid-free remission as recurring benchmarks 20641952. Third, endoscopy must be centrally read with blinded endoscopists and readers and a prespecified adjudication process 5540. Fourth, both randomized-withdrawal and treat-through designs are acceptable, giving sponsors flexibility provided placebo controls and, for treat-through, early-escape provisions are in place 206450. The most important divergence is the symptom instrument: UC uses the well-specified modified Mayo score, while Crohn's still anchors on the CDAI even as FDA openly signals its limitations and invites better, validated PRO-based symptom measures 605450.